Co.'s samRNA Vaccines Protect Better Against COVID Variants
  (1/7/22)
Gritstone bio Inc.'s lower-dose samRNA vaccines include a broader immune response to SARS-CoV-2 and may provide better protection against emerging variants. BTIG research has issued a "Buy" rating for Gritstone bio. More >

AI Driven Drug Firm Partners With Merck
Source: Streetwise Reports  (1/7/22)
Shares of Absci Corp. rose 18% after the company reported it is collaborating with Merck & Co. to create enzymes using its deep-learning Integrated Drug Creationâ„¢ platform and Bionic Proteinâ„¢ technologies. More >

Co. Partners to Test New Cancer Vaccines
  (1/6/22)
Genocea Biosciences Inc. is teaming up with Janssen Biotech to explore the immunogenicity of neoantigens and the role and impact of Inhibigensâ„¢ in potential vaccine therapies for cancer. H.C. Wainwright & Co. advised that it currently has a "Buy" rating on Genocea. More >

Medical Co. Strikes $3B Deal to Buy Digital Care Firm
Source: Streetwise Reports  (1/6/22)
Shares of Vocera Communications Inc. traded nearly 27% higher after the company reported it entered into a definitive agreement to be acquired by Stryker Corp. for $79.25 per share in cash. More >

Chen Lin's Top 6 Investment Ideas
Source: Streetwise Reports  (1/5/22)
In a recent interview with Streetwise Reports, family assets manager and contributing writer, Chen Lin, shared the six (mostly mid-cap) companies that are his top investment picks for 2022. More >

New Muscular Dystrophy Drug Shows Promise
Source: Streetwise Reports  (1/5/22)
Edgewise Therapeutics shares traded 24% higher after the company reported its EDG-5506 significantly lowered muscle damage biomarkers in adults after just two weeks of dosing in its Becker muscular dystrophy trial. More >

Co. Plans to Make 100M Rapid COVID Tests Monthly
  (1/5/22)
Biopharmaceutical firm Sorrento Therapeutics Inc. plans to mobilize a fully automated assembly line in San Diego, Calif., capable of producing 6 million rapid antigen detection COVISTIX testing units per month starting in Q1/22. More >

Lead Cancer Drug Gets Fast Tracked
Source: Streetwise Reports  (1/3/22)
Shares of Genprex Inc. traded 165% higher after the company reported the U.S. FDA has awarded Fast Track Designation for its REQORSAâ„¢ Immunogene Therapy for use in combination with Merck & Co.'s Keytruda® for non-small cell lung cancer treatment. More >

Analyst: Drug a 'Hidden Gem for 2022'
  (12/31/21)
Oppenheimer ranks Astria Therapeutics Outperform after learning about its drug for hereditary angioedema, saying "We stay bullish." More >

Co.'s COVID-19 Test Detects Omicron Variant
  (12/30/21)
H.C. Wainwright & Co. gives Sorrento Therapeutics a Buy rating after initial testing shows its COVISTIX detects COVID-19's Omicron variant. More >

Co. Looks To US For Help Fighting Strokes
Source: Streetwise Reports  (12/29/21)
Canadian company Algernon Pharmaceuticals Inc. has applied to uplist to the Nasdaq in hopes of attracting U.S. investors to its mission to repurpose drugs. More >

Co. Still Compelling After Drug Trial Failure
  (12/29/21)
"Arcalyst remains the value driver" for Kiniksa Pharmaceuticals, and "we continue to hold a favorable view of the company," noted a Wedbush report. More >

Co. Rated Outperform As Heart Failure Drug Nears Potential Approval
  (12/25/21)
"Cytokinetics' pipeline of muscle-directed therapies has potential to address several diseases with high unmet medical need and may generate significant revenue across pipeline programs," noted an Oppenheimer report. More >

Analyst: Question Lingers Over Biotech’s Cell Therapy
  (12/23/21)
A DawsonJames report notes that Brainstorm Cell Therapeutics’ autologous stem cells in amyotrophic lateral sclerosis will need further study to prove their effectiveness.
More >

Coverage Initiated on Biopharma Co. After Turnaround Story
  (12/23/21)
"With Acasti Pharma shares trading near cash levels yet current resources sufficient to achieve key development milestones across the pipeline over 2022-2023, we recommend investors build a position," noted an Oppenheimer report.
More >

Analyst Highlights Top Picks in Biotech for 2022
  (12/20/21)
Aldeyra Therapeutics, in the ophthalmology space, and SQZ Biotechnologies, in the cell therapy sector, have "advantages that their specific approaches allow," noted a BTIG report. More >

FDA Grants Approval for CNS-Focused Biopharma Firm's Bipolar Disorder Drug
Source: Streetwise Reports  (12/20/21)
Intra-Cellular Therapies Inc. shares traded 19% higher to a new 52-week high after the company reported the U.S. FDA has approved the use of its CAPLYTA® (lumateperone) for treatment of adults with bipolar depression. More >

Co. Launches Pivotal Phase in Alzheimer's Agitation Drug's Trial
  (12/17/21)
BioXcel Therapeutics' lead drug candidate for agitation in Alzheimer's disease patients could serve a substantial market, noted an H.C. Wainwright & Co. report. More >

Analyst Says Regeneron Could Be 'Biotech Champion'
  (12/17/21)
Regeneron Pharmaceuticals Inc.'s stock was up 36% in 2021 while the NASDAQ Biotechnology Index remained flat, Oppenheimer analyst Hartaj Singh reported in a Dec. 16 research note. More >

Co.'s Shares Gain 27% After FDA Nears Drug Approval
Source: Streetwise Reports  (12/16/21)
Shares of Calliditas Therapeutics AB traded higher after the company reported the U.S. FDA granted accelerated approval for its TARPEYOâ„¢ (budesonide) to reduce proteinuria in IgA nephropathy. More >

Target Price Raised on Biotech Based on Management Update
  (12/13/21)
During its recent R&D Day, Prometheus Biosciences announced new strong trial data, another new indication for its lead therapeutic candidate and progress in developing a subcutaneous formulation of it, according to an Oppenheimer report. More >

Arena Pharma Takes Center Stage With Pfizer's $6.7B Cash Buyout
Source: Streetwise Reports  (12/13/21)
Arena Pharmaceuticals shares traded 80% higher after the company reported it agreed to be acquired by Pfizer Inc. for $100.00 per share in cash in a deal valued at $6.7 billion. More >

Biopharma Explains How Its Technology Evolved, Describes Current Programs
  (12/11/21)
F-star Therapeutics "has methodically delivered scientific/preclinical/early clinical data validating its platform bispecific technology," noted an Oppenheimer report. More >

Biopharma's Anti-PD-L1 Antibody Advances in Two Oncologic Indications
Source: Streetwise Reports  (12/10/21)
Checkpoint Therapeutics' "cosibelimab represents a competitive asset on both efficacy and safety with an expected added advantage of lower net price," an H.C. Wainwright & Co. report noted. More >

Biopharma Partners to Commercialize Enzyme Used for Kidney Transplant Patients
  (12/10/21)
The partnership allows Hansa Biopharma to "enter new markets without the cost and risk of building out country-specific commercial organizations for a single product," an H.C. Wainwright & Co. report indicated. More >